AMIX Autonomix Medical Inc.

$AMIX The encouraging part: On Sept. 30, Autonomix reported positive FDA feedback supporting a potential 510(k) pathway for its standalone sensing platform. The company is targeting potential U.S. clearance in roughly 15 months, assuming development, validation and FDA review proceed successfully. That's important because AMIX now has a more concrete regulatory path rather than simply a speculative technology story. There are also encouraging preclinical/clinical signals: Its pancreatic-cancer pain work has shown meaningful pain reduction in early human data. Its renal-nerve preclinical work demonstrated the ability to detect and localize neural activity and confirm changes after ablation. The company continues expanding its patent portfolio. The problem: the market isn't rewarding those developments yet.

$AMIX Can't believe this will ever touch that low but desperately waiting for this big news so it can take it back to $10

$AMIX After full review of company - looks interesting. Yes, cash raise is questionable but must survive somehow in current climate. Company's tech could change lives for many patients with many conditions. Zero market appreciation for the technology (displayed in market cap) makes for a nice entry point. I'm in! 👍 Good Luck!!

$AMIX This is what we called a "stock terrorism " where low life goones fk the sh-t out of a very promising stock. Shame on their pathetic lives.

$AMIX Can't believe all these cheap SOBs doing pump and dump and don't let this stock breath a bit . Fckn low life cheapies and selfish mother truckers.

$AMIX catalysts I would watch U.S. clinical trial commencement AMIX has said its U.S. multicenter clinical study is planned to begin in 2026. The study is intended to formally evaluate pain relief and quality-of-life outcomes in pancreatic-cancer patients. AMIX is refining its catheter for human use in the U.S. and advancing toward FDA submission. A concrete FDA milestone could provide a meaningful catalyst. Renal/cardiovascular program AMIX has reported preclinical evidence that its technology can detect renal nerve activity and changes following intervention. The company sees this as a potential entry into cardiovascular applications, including hypertension. Clinical data presentations AMIX had two abstracts accepted for presentation at CIRSE 2026, covering pancreatic-cancer pain treatment and its broader nerve-mapping technology.

$AMIX (Daily Chart Analysis) 📊 Two conflicting structures are currently in play, with the broader downward channel remaining dominant. However, price action is testing the apex of the ascending support line (green) near current levels ($3.11). A successful defense here could trigger an initial bounce back toward the primary descending resistance, targeting the $5.80 – $6.40 reversal zone. Daily momentum remains neutral/compressed, indicating that a directional expansion move may be approaching. Critical support to watch remains at $2.44 (2026 low). (Not financial advice. Manage risk accordingly.)

$AMIX unlike the engineered massive run to 20, it looks like they are content to do periodic ATM without engineered run. I suspect Friday was such an instance. Release news, get volume and sell ATM into volume. It wouldnt surprise me if they sold 0.5M to 1M shares ATM on Fridays 2M share day.

$AMIX Told you this stock and company is TRASH! It's a dilution machine. No money for shareholders, only for the owners of the SCAM company.

$AMIX Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation

$AMIX Uhmm...bad news, I still have some stocks in portfolio,but it seems they're on the verge of bankruptcy 🫣🫣🫩